Similarity-based modeling in large-scale prediction of drug-drug interactions

Nature Protocols

Volumn 9, Issue 9, 2014, Pages 2147-2163

  Vilar, Santiago ^a,b   Uriarte, Eugenio ^b   Santana, Lourdes ^b   Lorberbaum, Tal ^a   Hripcsak, George ^a   Friedman, Carol ^a   Tatonetti, Nicholas P ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; CHEMICAL MODEL; CHEMICAL STRUCTURE; DRUG DATABASE; DRUG INTERACTION; PATIENT SAFETY; PHYSIOLOGY; PROCEDURES; STANDARDS; TOXICITY TESTING;

AREA UNDER CURVE; DATABASES, PHARMACEUTICAL; DRUG INTERACTIONS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PATIENT SAFETY; TOXICITY TESTS;

EID: 84907027073     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2014.151     Document Type: Review

References (28)

1. Pirmohamed, M. & Orme, M.L. Drug Interactions of Clinical Importance. Chapman & Hall 1998.
2. Tatonetti, N.P., Fernald, G.H. & Altman, R.B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J. Am. Med. Inform. Assoc. 19, 79-85 (2012).
3. US Food and Drug Administration (FDA) http://www.fda.gov/ (accessed April 2013).
4. Becker, M.L. et al. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol. Drug Saf. 16, 641-651 (2007).
5. Bjornsson, T.D. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815-832 (2003).
6. Vilar, S. et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc. 18, I73-I80 (2011).
7. Vilar, S., Harpaz, R., Santana, L., Uriarte, E. & Friedman, C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS ONE 7, e41471 (2012).
8. Vilar, S. et al. Drug-drug interaction through molecular structure similarity analysis. J. Am. Med. Inform. Assoc. 19, 1066-1074 (2012).
9. Vilar, S., Uriarte, E., Santana, L., Tatonetti, N.P. & Friedman, C. Detection of drug-drug interactions by modeling interaction profile fingerprints. PLoS ONE 8, e58321 (2013).
10. Vilar, S., Uriarte, E., Santana, L., Friedman, C. & Tatonetti, N.P. State of the art and development of a new drug-drug interaction large-scale predictor based on 3D pharmacophoric similarity. Curr. Drug Metabolism. 15, in press (2014).
11. Durant, J.L., Leland, B.A., Henry, D.R. & Nourse, J.G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 42, 1273-1280 (2002).
12. Liu, M. et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J. Am. Med. Inform. Assoc. 19(e1), e28-e35 (2012).
13. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
14. Dixon, S.L. et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647-671 (2006).
15. Fowler, S. & Zhang, H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 10, 410-424 (2008).
16. Hudelson, M.G. et al. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. J. Med. Chem. 51, 648-654 (2008).
17. Pang, K.S., Rodrigues, A.D. & Peter, R.M. (eds.), Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. Springer, 2010.
18. Jonker, D.M., Visser, S.A.G., van der Graaf, P.H., Voskuyl, R.A. & Danhof, M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106, 1-18 (2005).
19. Rahnasto, M., Raunio, H., Poso, A., Wittekindt, C. & Juvonen, R.O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem. 48, 440-449 (2005).
20. Afzelius, L. et al. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 59, 909-919 (2001).
21. De Rienzo, F., Fanelli, F., Menziani, M.C. & De Benedetti, P.G. Theoretical investigation of substrate specificity for cytochromes p450 IA2, p450 IID6 and p450 IIIA4. J. Comput. Aided Mol. Des. 14, 93-116 (2000).
22. Percha, B., Garten, Y. & Altman, R.B. Discovery and explanation of drug-drug interactions via text mining. Pac. Symp. Biocomput. 2012, 410-421 (2012).
23. Tari, L., Anwar, S., Liang, S., Cai, J. & Baral, C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics 26, i547-i553 (2010).
24. Percha, B. & Altman, R.B. Informatics confronts drug-drug interactions. Trends Pharmacol. Sci. 34, 178-184 (2013).
25. Gottlieb, A., Stein, G.Y., Oron, Y., Ruppin, E. & Sharan, R. INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol. Syst. Biol. 8, 592 (2012).
26. Hill, T. & Lewicki, P. Statistics Methods and Applications. A Comprehensive Reference for Science, Industry and Data Mining. StatSoft, 2006.
27. Tatonetti, N.P., Ye, P.P., Daneshjou, R. & Altman, R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4, 125ra31 (2012).
28. Olvey, E.L., Clauschee, S. & Malone, D.C. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther. 87, 48-51 (2010).